our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t
Company profile
Ticker
FEMY
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
FEMY stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
5 Apr 24
S-8
Registration of securities for employees
5 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Results of Operations and Financial Condition
28 Mar 24
8-K
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
20 Mar 24
8-K
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
6 Mar 24
8-K
Disrupting Convention in Women’s Health Through Continuous Innovation February 2024 Corporate Presentation 1
28 Feb 24
8-K
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
6 Feb 24
EFFECT
Notice of effectiveness
11 Dec 23
424B3
Prospectus supplement
8 Dec 23
Latest ownership filings
4
Richard D. Spector
13 Feb 24
3
Richard D. Spector
13 Feb 24
4
Daniel Scott Currie
2 Feb 24
4
Dov Elefant
2 Feb 24
4
Christine E Thomas
2 Feb 24
4
Kathy Lee-Sepsick
2 Feb 24
3
Initial statement of insider ownership
28 Nov 23
4
Joshua Silverman
22 Nov 23
3
Joshua Silverman
22 Nov 23
SC 13D
PharmaCyte Biotech, Inc.
22 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.69 mm | 8.69 mm | 8.69 mm | 8.69 mm | 8.69 mm | 8.69 mm |
Cash burn (monthly) | 670.86 k | 609.43 k | 1.36 mm | 1.09 mm | 951.91 k | 926.04 k |
Cash used (since last report) | 4.48 mm | 4.07 mm | 9.09 mm | 7.27 mm | 6.36 mm | 6.19 mm |
Cash remaining | 4.21 mm | 4.62 mm | -397.16 k | 1.42 mm | 2.33 mm | 2.51 mm |
Runway (months of cash) | 6.3 | 7.6 | -0.3 | 1.3 | 2.5 | 2.7 |
Institutional ownership, Q3 2023
7.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 13 |
Closed positions | 3 |
Increased positions | 5 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 5.17 bn |
Total shares | 1.64 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Clear Street | 249.90 k | $745.00 k |
Clear Creek Financial Management | 232.52 k | $692.91 mm |
BAC Bank Of America | 165.04 k | $491.83 mm |
CM Management | 125.00 k | $372.50 mm |
BCS Barclays | 99.00 k | $295.00 k |
Vanguard | 87.62 k | $261.12 mm |
Tri Locum Partners | 76.61 k | $228.28 mm |
Geode Capital Management | 75.90 k | $226.31 mm |
Sassicaia Capital Advisers | 71.93 k | $214.35 mm |
Renaissance Technologies | 69.13 k | $206.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Feb 24 | Richard D. Spector | Stock Option Common Stock | Grant | Acquire A | No | No | 1.1 | 100,000 | 110.00 k | 100,000 |
1 Feb 24 | Daniel Scott Currie | Stock Option Common Stock | Grant | Acquire A | No | No | 0.8 | 61,900 | 49.52 k | 61,900 |
1 Feb 24 | Dov Elefant | Stock Option Common Stock | Grant | Acquire A | No | No | 0.8 | 84,000 | 67.20 k | 84,000 |
1 Feb 24 | Christine E Thomas | Stock Option Common Stock | Grant | Acquire A | No | No | 0.8 | 32,600 | 26.08 k | 32,600 |
News
HC Wainwright & Co. Maintains Buy on Femasys, Raises Price Target to $12
1 Apr 24
Femasys Q4 EPS $(0.19) Beats $(0.21) Estimate, Sales $213.11K Miss $240.00K Estimate
28 Mar 24
Chardan Capital Reiterates Buy on Femasys, Maintains $12 Price Target
21 Mar 24
HC Wainwright & Co. Reiterates Buy on Femasys, Maintains $10 Price Target
21 Mar 24
First Lady Jill Biden Unveils $100M In Federal Funding To Support R&D - Watch Out for These Women Health Stocks
21 Feb 24
Press releases
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
20 Mar 24
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
6 Feb 24
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
26 Jan 24
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
23 Jan 24